REHAB-HF 试验中老年急性心衰患者康复治疗的经济结局:随机临床试验的二次分析
REHAB-HF 试验将 349 例 60 岁以上急性失代偿性心衰住院患者随机分入 12 周康复干预组或对照组,本二次分析评估其经济结局。干预成本平均 4204 美元。
核心结论
- 该康复干预的长期获益可能为医疗系统带来良好价值,尤其在射血分数保留亚组。
- 长期成本效果目前不确定,取决于获益能维持至研究随访之后的假设,需未来试验证实。
研究设计与样本
- REHAB-HF 多中心随机临床试验的预计划经济结局二次分析,纳入 349 例 60 岁以上急性失代偿性心衰住院患者。
- 患者于 2014 年 9 月 17 日至 2019 年 9 月 19 日入组,随机分入康复干预组或对照组。
- 医疗资源使用和药物成本分别按 2019 年美国 Medicare 支付和联邦供应计划估算,成本效果采用心衰成本效果模型模拟。
主要发现
- 干预成本平均为 4204 美元(SD 2059)。
临床怎么用
- 对于 60 岁以上急性失代偿性心衰住院患者,可考虑 12 周康复干预以改善生活质量,但需知晓其长期成本效果尚不确定。
局限性
- 长期成本效果依赖获益维持至研究随访之后的假设,需未来试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial, a novel 12-week rehabilitation intervention demonstrated significant improvements in validated measures of physical function, quality of life, and depression, but no significant reductions in rehospitalizations or mortality compared with a control condition during the 6-month follow up. The economic implications of these results are important given the increasing pressures for cost containment in health care. OBJECTIVE: To report the economic outcomes of the REHAB-HF trial and estimate the potential cost-effectiveness of the intervention. DESIGN, SETTING, PARTICIPANTS: The multicenter REHAB-HF trial randomized 349 patients 60 years or older who were hospitalized for acute decompensated heart failure to rehabilitation intervention or a control group; patients were enrolled from September 17, 2014, through September 19, 2019. For this preplanned secondary analysis of the economic outcomes, data on medical resource use and quality of life (via the 5-level EuroQol 5-Dimension scores converted to health utilities) were collected. Medical resource use and medication costs were estimated using 2019 US Medicare payments and the Federal Supply Schedule, respectively. Cost-effectiveness was estimated using the validated Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, which uses an individual-patient simulation model informed by the prospectively collected trial data. Data were analyzed from March 24, 2019, to December 1, 2020. INTERVENTIONS: Rehabilitation intervention or control. MAIN OUTCOMES AND MEASURES: Costs, quality-adjusted life-years (QALYs), and the lifetime estimated cost per QALY gained (incremental cost-effectiveness ratio). RESULTS: Among the 349 patients included in the analysis (183 women [52.4%]; mean [SD] age, 72.7 [8.1] years; 176 non-White [50.4%] and 173 White [49.6%]), mean (SD) cumulative costs per patient were $26 421 ($38 955) in the intervention group (excluding intervention costs) and $27 650 ($30 712) in the control group (difference, -$1229; 95% CI, -$8159 to $6394; P = .80). The mean (SD) cost of the intervention was $4204 ($2059). Quality of life gains were significantly greater in the intervention vs control group during 6 months (mean utility difference, 0.074; P = .001) and sustained beyond the 12-week intervention. Incremental cost-effectiveness ratios were estimated at $58 409 and $35 600 per QALY gained for the full cohort and in patients with preserved ejection fraction, respectively. CONCLUSIONS AND RELEVANCE: These analyses suggest that longer-term benefits of this novel rehabilitation intervention, particularly in the subgroup of patients with preserved ejection fraction, may yield good value to the health care system. However, long-term cost-effectiveness is currently uncertain and dependent on the assumption that benefits are sustained beyond study follow-up, which needs to be corroborated in future trials in this patient population.
引用
- Chew, Li, Zeitouni, et al. Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 34817542. doi:10.1001/jamacardio.2021.4836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。